Smith & Nephew SNATS Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $26.45
- Today's High:
- $26.8
- Open Price:
- $26.68
- 52W Low:
- $21.1396
- 52W High:
- $33.09
- Prev. Close:
- $26.79
- Volume:
- 361251
Company Statistics
- Market Cap.:
- $11.70 billion
- Book Value:
- 2.3976
- Revenue TTM:
- $5.35 billion
- Operating Margin TTM:
- 13.05%
- Gross Profit TTM:
- $3.70 billion
- Profit Margin:
- 4.07%
- Return on Assets TTM:
- 4.37%
- Return on Equity TTM:
- 4.1%
Company Profile
Smith & Nephew SNATS Inc had its IPO on 1999-11-16 under the ticker symbol SNN.
The company operates in the Healthcare sector and Medical Devices industry. Smith & Nephew SNATS Inc has a staff strength of 19,000 employees.
Stock update
Shares of Smith & Nephew SNATS Inc opened at $26.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $26.45 - $26.8, and closed at $26.48.
This is a -1.16% slip from the previous day's closing price.
A total volume of 361,251 shares were traded at the close of the day’s session.
In the last one week, shares of Smith & Nephew SNATS Inc have slipped by -1.45%.
Smith & Nephew SNATS Inc's Key Ratios
Smith & Nephew SNATS Inc has a market cap of $11.70 billion, indicating a price to book ratio of 2.2514 and a price to sales ratio of 2.2089.
In the last 12-months Smith & Nephew SNATS Inc’s revenue was $5.35 billion with a gross profit of $3.70 billion and an EBITDA of $1.14 billion. The EBITDA ratio measures Smith & Nephew SNATS Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Smith & Nephew SNATS Inc’s operating margin was 13.05% while its return on assets stood at 4.37% with a return of equity of 4.1%.
In Q2, Smith & Nephew SNATS Inc’s quarterly earnings growth was a negative -2.5% while revenue growth was a positive 5.2%.
Smith & Nephew SNATS Inc’s PE and PEG Ratio
- Forward PE
- 16.5017
- Trailing PE
- 53.58
- PEG
- 1.1225
Its diluted EPS in the last 12-months stands at $0.5 per share while it has a forward price to earnings multiple of 16.5017 and a PEG multiple of 1.1225. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Smith & Nephew SNATS Inc’s profitability.
Smith & Nephew SNATS Inc stock is trading at a EV to sales ratio of 2.7611 and a EV to EBITDA ratio of 11.6547. Its price to sales ratio in the trailing 12-months stood at 2.2089.
Smith & Nephew SNATS Inc stock pays annual dividends of $0.375 per share, indicating a yield of 2.82% and a payout ratio of 2.6%.
Balance sheet and cash flow metrics
- Total Assets
- $9.84 billion
- Total Liabilities
- $1.77 billion
- Operating Cash Flow
- $-182000000.00
- Capital Expenditure
- $83.50 million
- Dividend Payout Ratio
- 2.6%
Smith & Nephew SNATS Inc ended 2024 with $9.84 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $9.84 billion while shareholder equity stood at $5.23 billion.
Smith & Nephew SNATS Inc ended 2024 with $0 in deferred long-term liabilities, $1.77 billion in other current liabilities, 175000000.00 in common stock, $4.96 billion in retained earnings and $3.05 billion in goodwill. Its cash balance stood at $190.00 million and cash and short-term investments were $190.00 million. The company’s total short-term debt was $407,000,000 while long-term debt stood at $2.49 billion.
Smith & Nephew SNATS Inc’s total current assets stands at $3.88 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.27 billion compared to accounts payable of $955.00 million and inventory worth $2.41 billion.
In 2024, Smith & Nephew SNATS Inc's operating cash flow was $-182000000.00 while its capital expenditure stood at $83.50 million.
Comparatively, Smith & Nephew SNATS Inc paid $0.03 in dividends in 2024.
Other key metrics
- Current Trading Price
- $26.48
- 52-Week High
- $33.09
- 52-Week Low
- $21.1396
- Analyst Target Price
- $35.17
Smith & Nephew SNATS Inc stock is currently trading at $26.48 per share. It touched a 52-week high of $33.09 and a 52-week low of $33.09. Analysts tracking the stock have a 12-month average target price of $35.17.
Its 50-day moving average was $28.73 and 200-day moving average was $28.87 The short ratio stood at 1.69 indicating a short percent outstanding of 0%.
Around 2.9% of the company’s stock are held by insiders while 985% are held by institutions.
Frequently Asked Questions About Smith & Nephew SNATS Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.